Lawrence Lu

840 total citations
8 papers, 709 citations indexed

About

Lawrence Lu is a scholar working on Nephrology, Immunology and Oncology. According to data from OpenAlex, Lawrence Lu has authored 8 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Nephrology, 4 papers in Immunology and 3 papers in Oncology. Recurrent topics in Lawrence Lu's work include Acute Kidney Injury Research (4 papers), Phagocytosis and Immune Regulation (2 papers) and Immune cells in cancer (2 papers). Lawrence Lu is often cited by papers focused on Acute Kidney Injury Research (4 papers), Phagocytosis and Immune Regulation (2 papers) and Immune cells in cancer (2 papers). Lawrence Lu collaborates with scholars based in United States, Netherlands and United Kingdom. Lawrence Lu's co-authors include Sarah Faubel, Charles L. Edelstein, Dong‐Jin Oh, Danica Galešić Ljubanović, Charles A. Dinarello, Christina L. Klein, Leonid L. Reznikov, Hilary Somerset, Eli C. Lewis and Belda Dursun and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Pharmacology and Experimental Therapeutics and American Journal of Physiology-Renal Physiology.

In The Last Decade

Lawrence Lu

8 papers receiving 697 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lawrence Lu United States 7 302 234 175 162 102 8 709
Gloria Rashid Israel 16 310 1.0× 284 1.2× 177 1.0× 81 0.5× 85 0.8× 39 1.0k
Alice M. Sheridan United States 14 133 0.4× 302 1.3× 342 2.0× 64 0.4× 161 1.6× 23 917
Gui‐Ling Ren China 10 179 0.6× 280 1.2× 394 2.3× 72 0.4× 58 0.6× 12 768
Aaron Haig Canada 19 134 0.4× 146 0.6× 402 2.3× 236 1.5× 330 3.2× 44 1.1k
Zhixia Song China 15 160 0.5× 220 0.9× 262 1.5× 164 1.0× 111 1.1× 21 710
Harumi Kitamura Japan 12 196 0.6× 414 1.8× 315 1.8× 56 0.3× 128 1.3× 19 1.1k
Carole Hénique France 17 83 0.3× 384 1.6× 355 2.0× 225 1.4× 138 1.4× 24 1.1k
Kristin M. Burkhart United States 15 134 0.4× 166 0.7× 370 2.1× 57 0.4× 144 1.4× 17 776
Bobby Nibhanupudy United States 2 151 0.5× 120 0.5× 69 0.4× 45 0.3× 61 0.6× 2 341
Cristina Alonso‐Montes Spain 15 99 0.3× 365 1.6× 302 1.7× 44 0.3× 80 0.8× 39 851

Countries citing papers authored by Lawrence Lu

Since Specialization
Citations

This map shows the geographic impact of Lawrence Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Lu more than expected).

Fields of papers citing papers by Lawrence Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Lu. The network helps show where Lawrence Lu may publish in the future.

Co-authorship network of co-authors of Lawrence Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Lu. A scholar is included among the top collaborators of Lawrence Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Lu. Lawrence Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Sanborn, Rachel E., Omid Hamid, Elisabeth G.E. de Vries, et al.. (2021). CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. Journal for ImmunoTherapy of Cancer. 9(7). e002446–e002446. 20 indexed citations
2.
Münster, Pamela N., Jasgit C. Sachdev, Gini F. Fleming, et al.. (2019). Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA).. Journal of Clinical Oncology. 37(15_suppl). 4130–4130. 5 indexed citations
3.
Lu, Lawrence, Sarah Faubel, Zhibin He, et al.. (2012). Depletion of Macrophages and Dendritic Cells in Ischemic Acute Kidney Injury. American Journal of Nephrology. 35(2). 181–190. 47 indexed citations
4.
He, Zhibin, Belda Dursun, Dong‐Jin Oh, et al.. (2009). Macrophages are not the source of injurious interleukin-18 in ischemic acute kidney injury in mice. American Journal of Physiology-Renal Physiology. 296(3). F535–F542. 16 indexed citations
5.
He, Zhibin, Lawrence Lu, Christopher Altmann, et al.. (2008). Interleukin-18 binding protein transgenic mice are protected against ischemic acute kidney injury. American Journal of Physiology-Renal Physiology. 295(5). F1414–F1421. 63 indexed citations
6.
Lu, Lawrence, Dong‐Jin Oh, Belda Dursun, et al.. (2007). Increased Macrophage Infiltration and Fractalkine Expression in Cisplatin-Induced Acute Renal Failure in Mice. Journal of Pharmacology and Experimental Therapeutics. 324(1). 111–117. 93 indexed citations
7.
Oh, Dong‐Jin, Belda Dursun, Zhibin He, et al.. (2007). Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. American Journal of Physiology-Renal Physiology. 294(1). F264–F271. 117 indexed citations
8.
Faubel, Sarah, Eli C. Lewis, Leonid L. Reznikov, et al.. (2007). Cisplatin-Induced Acute Renal Failure Is Associated with an Increase in the Cytokines Interleukin (IL)-1β, IL-18, IL-6, and Neutrophil Infiltration in the Kidney. Journal of Pharmacology and Experimental Therapeutics. 322(1). 8–15. 348 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gloria Rashid Breakdown of academic impact, for papers by Alice M. Sheridan Breakdown of academic impact, for papers by Gui‐Ling Ren Breakdown of academic impact, for papers by Aaron Haig Breakdown of academic impact, for papers by Zhixia Song Breakdown of academic impact, for papers by Harumi Kitamura Breakdown of academic impact, for papers by Carole Hénique Breakdown of academic impact, for papers by Kristin M. Burkhart Breakdown of academic impact, for papers by Bobby Nibhanupudy Breakdown of academic impact, for papers by Cristina Alonso‐Montes
Rankless by CCL
2026